A Drug Interaction between Crizotinib and Warfarin in Non-Small-Cell Lung Cancer: A Case Report
-
- Kubomura Yu
- Section of Pharmaceutical Services, Nippon Medical School Hospital
-
- Ise Yuya
- Section of Pharmaceutical Services, Nippon Medical School Hospital
-
- Wako Tetsuya
- Section of Pharmaceutical Services, Nippon Medical School Hospital
-
- Katayama Shirou
- Section of Pharmaceutical Services, Nippon Medical School Hospital
-
- Noro Rintaro
- Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School
-
- Kubota Kaoru
- Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School
この論文をさがす
説明
<p>We report a case of increased prothrombin time-international normalized ratio (PT-INR) when crizotinib and warfarin were co-administered. A 74-year-old Japanese woman presented to the hospital with dyspnea, and was diagnosed with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Three years after surgical resection of the tumor, the patient started crizotinib because of the recurrence of NSCLC. She received 2 mg/day warfarin due to a medical history of cerebral infarction and chronic atrial fibrillation. Before crizotinib initiation, the patient's PT-INR was 2.60. After 7 days of daily doses of crizotinib, the patient's PT-INR increased to 3.65. This case report provides the first evidence of a drug interaction between crizotinib and warfarin.</p>
収録刊行物
-
- 日医大誌
-
日医大誌 84 (6), 291-293, 2017
日本医科大学医学会
